Analyzing the effectiveness of caplacizumab for treating acquired thrombotic thrombocytopenic purpura
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020
This study is trying to see how well caplacizumab works for people with acquired thrombotic thrombocytopenic purpura and what factors might affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Cologne Academic / other |
| Drugs / interventions | caplacizumab |
| Locations | 1 site (Cologne) |
| Trial ID | NCT04985318 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the use of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura (aTTP) across multiple centers in Germany. It will assess the real-world efficacy of the treatment, identify factors predicting patient outcomes, and develop new treatment algorithms to enhance patient care and reduce costs. The study will include patients who have received at least one dose of caplacizumab and will analyze their clinical data retrospectively.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura who have received caplacizumab.
Not a fit: Patients with hereditary thrombotic thrombocytopenic purpura or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with aTTP, enhancing their overall outcomes.
How similar studies have performed: While this study focuses on a specific treatment in a real-world setting, similar studies have shown promise in evaluating the efficacy of caplacizumab for aTTP.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura * Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.) * Male or female patients ≥ 18 years of age * signed written informed consent Exclusion Criteria: * Hereditary thrombotic thrombocytopenic purpura * disability to give informed consent
Where this trial is running
Cologne
- University Hospital of Cologne — Cologne, Germany (Recruiting)
Study contacts
- Principal investigator: Linus Völker, MD — Department II of Internal Medicine, University of Cologne
- Study coordinator: Linus Völker, MD
- Email: linus.voelker@uk-koeln.de
- Phone: +49 221 478 86285
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.